InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Appointment of UK Lead Broker Change of Company Secretary 1 Mar 2023 6:16PM $0.009 $0.420 risen by 4,566.67%
$18 s708A(5)(e) Cleansing Notice 28 Feb 2023 7:03PM $0.009 $0.420 risen by 4,566.67%
$18 Application for quotation of securities - MXC 28 Feb 2023 6:58PM $0.009 $0.420 risen by 4,566.67%
$18 Half Year Accounts 28 Feb 2023 6:38PM $0.009 $0.420 risen by 4,566.67%
$18 Notice of General Meeting/Proxy Form 28 Feb 2023 1:26PM $0.010 $0.420 risen by 4,321.05%
$18 Distribution of General Meeting Documents - Notice of Access 28 Feb 2023 1:19PM $0.010 $0.420 risen by 4,321.05%
$18 Investor Presentation 10 Feb 2023 6:49PM $0.010 $0.420 risen by 4,100%
$18 Notification regarding unquoted securities - MXC 6 Feb 2023 1:35PM $0.010 $0.420 risen by 4,100%
$18 Provision of US$600,000 Funding and change of CFO 3 Feb 2023 2:43PM $0.011 $0.420 risen by 3,718.18%
$18 s708A(12C)(e) Cleansing Notice 2 Feb 2023 1:27PM $0.010 $0.420 risen by 4,100%
$18 Proposed issue of securities - MXC 2 Feb 2023 1:02PM $0.010 $0.420 risen by 4,100%
$18 Proposed issue of securities - MXC 2 Feb 2023 12:52PM $0.010 $0.420 risen by 4,100%
$18 Refinancing and Extension to Convertible Security Agreements 2 Feb 2023 12:36PM $0.010 $0.420 risen by 4,100%
$18 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2023 9:40AM $0.010 $0.420 risen by 4,100%
$18 Change of External Financial Auditor 11 Jan 2023 12:50PM $0.012 $0.420 risen by 3,400%
$18 Results of CimetrA bioanalytics pre-clinal trial 10 Jan 2023 8:50AM $0.011 $0.420 risen by 3,718.18%
$18 Final Director's Interest Notice 3 Jan 2023 8:24AM $0.011 $0.420 risen by 3,718.18%
$18 Internal Costs Review Completed and Board Change 3 Jan 2023 8:23AM $0.011 $0.420 risen by 3,718.18%
$18 Notification regarding unquoted securities - MXC 29 Dec 2022 7:11PM $0.012 $0.420 risen by 3,400%
$18 Proposed issue of securities - MXC 23 Dec 2022 4:23PM $0.012 $0.420 risen by 3,400%
$18 s708A(12)(e) Cleansing Notice 23 Dec 2022 4:10PM $0.012 $0.420 risen by 3,400%
$18 $800,000 of funding received through Mercer Facility 23 Dec 2022 4:00PM $0.012 $0.420 risen by 3,400%
$18 Completion of CimetrA Efficacy Pre-clinical Trial 7 Dec 2022 3:24PM $0.012 $0.420 risen by 3,400%
$18 US$1,000,000 ArtemiC order delivered to US partner, AMC 5 Dec 2022 8:20AM $0.013 $0.420 risen by 3,260%
$18 Publication of Peer Reviewed Glioblastoma Research 2 Dec 2022 5:33PM $0.013 $0.420 risen by 3,260%

126 - 150 of 818 results

Page 6 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.